Rheumatoid Arthritis News

CHICAGO — Among patients with rheumatoid arthritis with moderate/high disease activity, one-third to two-thirds failed to change therapies over the following year to attain low disease activity as recommended by the American College of Rheumatology and EULAR, according to data presented here.

The FDA has approved the third biosimilar to adalimumab, adalimumab-adaz, for all eligible indications of the biologic product, according to a company press release.

CHICAGO — Terence Rooney, MD, senior medical director for Eli Lilly, highlights recent findings from an updated integrated safety analysis of baricitinib from a long-term study of patients with rheumatoid arthritis treated up to six years.

CHICAGO — Researchers have issued draft clinical practice guidelines for the management of reproductive issues among patients with rheumatic diseases. Prompted by a summit on reproductive health held by the American College of Rheumatology in 2014, experts have been studying a breadth of topics based on common and important questions surrounding these issues.

CHICAGO — Among patients with rheumatoid arthritis who experienced an inadequate response to methotrexate, a daily 15-mg dose of the JAK1 inhibitor upadacitinib was superior to both placebo and adalimumab at improving disease signs and symptoms.

CHICAGO — Repository corticotropin injection was determined to be a potentially safe and effective treatment option among patients with persistently active rheumatoid arthritis who were unresponsive to treatment with corticosteroids and conventional synthetic or biologic disease-modifying antirheumatic drugs, according to findings presented here.

CHICAGO — Collecting patient-generated health data via smart watches or mobile apps has the potential to benefit clinical care by improving patient outcomes and experience, as well as applying cost savings, according to William Dixon, MD, professor of digital epidemiology at The University of Manchester.

CHICAGO — A high number of dominant B-cell receptor clones in peripheral blood can predict significant short-term risk for rheumatoid arthritis in patients, according to data presented at the ACR/ARHP 2018 Annual Meeting.

CHICAGO — The use of a high-dose trivalent inactivated influenza vaccine significantly improved immune response among patients with rheumatoid arthritis, compared with the standard-dose quadrivalent inactivated vaccine, according to data presented at the ACR/ARHP 2018 Annual Meeting.

CHICAGO — Rheumatologists, as well as the rheumatology specialty as a whole, must become more aware of, and develop treatments and guidelines for, the problem of rheumatologic side effects related to checkpoint inhibitor therapy, according to Peter A. Merkel, MD, MPH, of the University of Pennsylvania.